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self-sufficiency and innovation 
in vaccine production and 
public health
IsaIas Raw e HIsako G. HIGasHI
Butantan has modern laboratories for production of vaccines and serums. 
Why produce vaccines?
seLF-suFFICIenCY as a security factor for public health became evident in 1984, when the national Quality Control Institute demonstrated that snakebite serums and others produced in Brazil were, because of low titres 
and high contamination by bacteria and fungi, unsuitable for human use, creating 
an climate of insecurity, given that snakebite serums must be produced specifically 
for the local species. the only private producer, a multinational company that had 
purchased the Instituto Pinheiros, faced with the fact that it would have to renew 
its technology and reformulate its installations to meet Good Manufacturing 
Practices standards, preferred to leave the country. the government-owned 
producers were mobilized to produce more serums of better quality, with 
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financial assistance from the Ministry of Health. In an emergency measure, 
Butantan installed a plant with new technology, and most of the government 
producers desisted. similar developments took place in africa and part of asia, 
where the large companies that supply snakebite serums, given the need to invest 
without having profitable returns, simply abandoned production, leaving the 
population unprotected.
 this was repeated with the sole producer of human albumin, which 
produced in deplorable conditions and without any reaction. Biobraz 
closed, leaving Brazil dependent on imported insulin. We also witnessed the 
abandonment of antibiotic plants, which made the country even more vulnerable.
 a new threat to public health arose with the avian flu, when producers of 
flu vaccines declared at a World Health organization Meeting that they would be 
compelled by local governments to reserve the vaccine against a pandemic, which 
has 80 micrograms of antigen, for their own populations, somehow imagining 
that they could survive without the rest of humanity.  Butantan took the 
initiative, and in very short time installed a pilot plant to begin production of this 
vaccine, obtaining the vaccinal virus for the H5n1 
Influenza from  vietnam (WHo) and from Indonesia (CdC – Centers for 
disease Control and Prevention), whose virus is now monopolized by the country 
of origin, which also must imagine it can survive alone or win part of the big 
business that the anticipated sale of the vaccine, at us$100 per dose, generates.   
 Public health cannot remain at the whim of profits, not even if limited to 
the population that can pay for the vaccines.  as Japan demonstrated, the seasonal 
flu is disseminated by children who bring the virus home from school. Protection 
for families depends on the protection of those with whom their children enter 
in contact! once these children are vaccinated, they cannot pass the virus to their 
families, reducing the frequency of pneumonia, without the government having 
to spend millions of dollars each year on a poorly effective multivalent vaccine. 
nor will the children develop middle ear infections, which can lead to childhood 
deafness. 
The Pasteur model
 Louis Pasteur (1822-1895), invented the public laboratory, it was a 
foundation that developed, produced and reapplied its income to continue 
research and produce. one hundred Pasteur Institutes were created in developing 
countries. By the 1980s most of them were not operating. the legal structure 
that permitted economic self-sufficiency was corroding. For their survival, these 
Institutes needed to modernize and expand production, they needed to have a 
basic research sector, which existed in Brazil, where Fiocruz and Butantan are 
research institutes. they needed to invest in development. since 1985, Butantan 
implanted the Biotechnology Center, where twenty doctors and 50 students were 
dedicated to research development, which the Bioindustrial division transformed 
into products for society.
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Louis Pasteur (1822-1895), 
French chemist and biologist, in 
strasbourg, France in 1852.
We need a reserve of supplies for the Ministry of Health that allows 
it to pay the prices it determines and pay when it can. the Ministry does not 
have resources to finance production that must be initiated eight to ten months 
before supply, which therefore falls in the following fiscal year, and is subject to 
tempestuous budget approvals (officially the Ministry ordered the seasonal flu 
vaccine in 2008), only after it received and used the vaccine. 
 Most of the government-owned producers entered in crisis, terminated 
production and became bottlers of  vaccines imported in bulk. this “Coca-Cola 
model” - buy syrup, dilute and bottle - does not allow the Institutes to learn to 
produce, much less gain technological independence, which is the foundation for 
innovation. they are hostage to the large companies that supply in bulk and that 
in fact set the supply prices for the Ministry. Rarely do they acquire technology, 
and when they do, it is usually as a “black-box”, which does not allow innovation. 
they are dependent on strategic inputs that allow the technology supplier to be 
the true owner of this technology and control how much is produced, the price to 
be paid by the Ministry, and therefore, the royalties that are due to them.
 In contrast, Butantan developed its own technology and commands 
production. this control required designing and building new production plants. 
Butantan constantly teaches Brazilian builders what is needed, such as filtered air 
to maintain sterility and even teaches Brazilian companies to produce equipment 
that had always been imported.  
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table 1 – Production of vaccinal antigens supplied to the Ministry of Health
(1984-2006)
Antigens Butantan Others Total
Pertussis, tetanus, 
diphtheria, recombinant 
hepatitis B, rabies and 
BCG
588.700.000
(82,3%)
BCG, yellow fever – 127.100.000
(17,3%)
MNR, polio, Hib
And others purchased
in bulk
– 375.200.000
(83,7%)
Total 661.700.000 502.300.000 1.164.000.000
Seasonal and avian flu
In 2000, Butantan cooperated with the Ministry of Health to introduce 
the flu vaccine for people older than 60. It reached an agreement under 
exceptional conditions that would never be repeated for technology transfer, 
strictly limited to the purchase of the vaccine in bulk until its factory was 
completed. this agreement had two important consequences. the first was that 
we negotiated a special price that resulted in savings of nearly Us$300 million, 
which we transferred to the Ministry, lowering the price of the vaccine, without 
leaving any debt. second, by using european technology, we resolved the 
problem caused by the fact that it was impossible to test the vaccine for that year 
– this was conducted by the WHo which supplies the strains a few months before 
vaccination. the Ministry of Health invested approximately R$34 million in the 
flu vaccine plant and the secretary of Health some R$40 million. unfortunately, 
the inexperience of the builder and its associates caused a delay of nearly three 
years for the plant to be ready for validation. this agreement allowed vaccinating, 
an average of more than 80% of the population older than 60 each year, 
beginning with 7.5 million doses and in 2007 reaching nearly 18.3 million, in a 
partnership between the Ministry,  Butantan and the states and municipalities. 
the incidence of flu decreased significantly as well as hospitalizations for 
pneumonia. 
 When we decided to produce the avian flu vaccine,  in three months we 
built a plant to meet the strategic demand of 200,000 doses per year, which 
would be sufficient to vaccinate a group that entered the country and was exposed 
to this pandemic form. the Ministry of Health and the financing agencies 
could not react with the same speed and the Foundation initiated the necessary 
investment. 
 In 2007, the u.s. government announced that it would finance Butantan, 
but the funds wound up being delivered to the WHo, which chose Butantan and 
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four other potential vaccine producers from developing countries. the project 
began production in 2008.
 DTP,  a basic vaccine
 the combined diphtheria-tetanus-whopping cough vaccine (dtP) was 
developed in the 1930’s and became the foundation for creating tetravalent, 
pentavalent and hexavalent vaccines. the use of multiple vaccines simplifies 
administration and reduces the significant cost of the syringes. to allow 
production under Good Manufacturing Practices (GMP), we had to build new 
installations, take advantage of “skeletons” that were abandoned for decades, new 
laboratories were built, and use new technology developed at Butantan, which 
demanded  a new generation of equipment. a center was built for formulation and 
bottling, which washed and  sterilized flasks, transferred the vaccines and then 
sealed and labeled, allowing the production of 28 thousand flasks per hour. With 
five to ten doses per flask, we could reach more than two million doses per day!
 since 1990, nearly 400 million doses of this vaccine have been produced 
and administered to practically all children younger than two. By choosing a 
strain of Bordetella pertussis and using a new inactivation process, we were able to 
practically eliminate the serious collateral effects. the three childhood infections 
practically disappeared.
source : Ms/svs/dveP/CGvdt/Cover.
* Morbity: subject to review. data subject to review.
Graph 1 – Incidence of diphtheria, tetanus and whopping cough (Ministry of  
                 Health data). 
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 three plants were built to produce these vaccines, which were totally self-
contained,  with capacity to meet Brazilian demand of nearly 25 million doses per 
year, for four doses per child and to supply the vaccines needed each year at 25 
thousand vaccination posts in the country. In addition to the children’s vaccine, 
we produced the dual dt vaccine for adult use (diphtheria-tetanus), which in 
2004 allowed revaccinating all of the 20 million people older than 60, given that 
diphtheria began to attack the elderly. Butantan alone produced 20 million, while 
in the following years this dropped to only two million. this was possible thanks 
to improvements in production, which is only possible with the implantation of 
technology.  Butantan can now produce up to 180 million dtP triple vaccines 
(diphtheria, tetanus, pertussis) (or its combinations) per year, and began exports. 
 Hepatite B and haemophilus b
 In 1995, we began to produce the recombinant vaccine against hepatitis B 
with technology developed at the Institute by a contracted researcher. the vaccine 
was immediately tested and approved at the university of Londrina, but had to 
wait five years and undergo five thousand trials to be recognized as efficient as 
the comparable vaccine. nearly 160 million doses already produced attest to the 
effectiveness and safety. there are now dozens of producers of the hepatitis B 
vaccine, and the cost dropped from  us$ 20 to us$ 0.22! at private clinics in 
Brazil or the united states the vaccine continues to cost nearly us$50.00 per 
dose!
 an obvious development would be the combination dtP-hepatitis B, 
adopted by most countries. Biomanguinhos decided to purchase the vaccine 
against haemophilus b in bulk and we suspended the development of our Hib 
vaccine (Haemophilus influenzae b). We ceded dtP to release the vaccine dtP-
Hib, leaving the hepatitis B vaccine separate. 
 We returned to developing the Hib vaccine and began assembling a plant 
for its production. the Hib vaccine, which conjugates the polysaccharide of this 
bacteria with the tetanic anatoxin, is definitively an effective vaccine. Butantan is 
one of the largest producers of tetanic anatoxin, which is used for the conjugate  
vaccine.  With this improvement, we have installed capacity to produce 180 
million doses per year. Butantan will soon begin producing the dtP-hepatitis B 
vaccine that can be combined at public health clinics with the Hib, from Butantan 
or from Biomamguimhos, making the vaccine pentavalent. Butantan does not 
have export restrictions on its vaccine.
 Because of the lack of competition, for more than a decade the price 
has remained  above us$ 2,50 and the Hib vaccine is now used by only one of 
five children. In africa, meningitis a is predominant, which is not common in 
Brazil. the vaccine conjugates the polysaccharide of meningitis a with the tetanic 
anatoxin with a very low yield. the Program for appropriate technology in 
Health (PatH) decided to invest in improving production and reached a process 
that allowed serving africa (specifically by an Indian company) at a cost of only 
estudos avançados 22 (64), 2008 161
us$ 0.50. the basic technology to produce the Hib and meningitis a vaccines 
are similar, and the vaccination will reach more children if, given market rules, 
production increases, if it is offered – as it should be – at a price below us$ 1. 
this is what Butantan intends to do, meeting the requests of asian and african 
countries. 
 the Gates Foundation imagined that us$ 5 would be sufficient to offer 
basic vaccines for the children of much poorer countries, and that by increasing 
the market of large producers, the price of the vaccine for developing countries  
would be reduced. It began to purchase the vaccines and offer them to developing 
countries and, with the results obtained, the governments wound up assuming, 
with their own resources, the public vaccination. It is increasingly evident that, 
despite the increased market, the prices did not fall, and that the companies 
would not invest based on the expectation that the market would be maintained 
after the Gates-World Bank- Rockefeller Foundation stopped financing. For 
the first time, ideas were suggested at international meetings to re-establish 
government production of vaccines, which countered the historic inability of 
state-owned companies to produce with quality and safety. they were notorious 
for their lack of managerial capacity and in particular, for an inability to innovate 
and develop new vaccines. the large companies changed their focus to high cost 
vaccines, which would never be available for the population and governments 
with limited resources. even the Pan american Health organization (PaHo) 
and the World Health organization (WHo) began to promote the purchase of 
these vaccinations at unviable costs, and now promote the vaccine for rotavirus 
at us$ 15 or more per child and the 7-valent pneumococcal conjugate vaccine at  
us$ 159 for three doses, and even the HPv vaccine at us$600 or more for each 
girl or woman! Private companies, by nature, give priority to profits, not public 
health. evidence of this is that one of the countries with the largest number of 
competent producers of vaccines, India, offers its products for export and has 
been able to produce quality vaccines for the rotating funds of unicef and PaHo, 
and because of the competition, reduce costs. some now produce for the large 
multinational companies. nevertheless, a simple analysis shows that India does 
not have priority access to these vaccines, which is evident by the fact that it is the 
world’s last region affected by polio. 
 New pertussis and flu vaccine
 the dtP vaccine from Butantan has proved to be effective and safe, 
which was not the case in Japan, where the pertussis vaccine was highly toxic. 
H. sato, in Japan, isolated two essential proteins for immunizationa against  
pertussis.  the large companies increased from to three to five the number 
of vaccinal antigens without a strong benefit. the new vaccines, with isolated 
proteins, denominated acellular (adtP), have a lower frequency of serious 
collateral effects and the same effectiveness as the classic vaccine  (wdtP). the 
cost of wdtP, at the PaHo rotating fund is us$ 0.15 per dose. the adtP 
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vaccine costs us$ 8.15. Without any cost-benefit perspective, some societies, 
accepting the propaganda of the producers, recommended substituting wdtP 
for adtP, which for Brazil would represent a cost of us$ 130.44 million! In 
november 2007, the PaHo and WHo met to declare that this substitution has 
no justifiable benefit. 
 Butantan, always concerned with cost-benefit factors and economizing 
public funds at the Ministry for the introduction of new vaccines, developed a 
technology that allowed removing from Bordetella  lipopolysaccharide (LPs), a 
substance that links to toll-Like Receptor 4 from the cell membrane, triggering 
an inflammatory response. the new pertussis, whose clinical trial was conducted 
by the Pediatrics department of the university of Campinas  (unicamp),  and 
which we call Plow, does not increase the cost of the vaccine, which remains 
like dtP at us$ 0.15 per dose. an agreement allowed the netherland vaccine 
Institute, pioneer in industrial production of vaccines, to use Butantan’s 
technology.
 With a current capacity to produce 180 million doses of the dPtlow 
vaccine,  we accumulated 72 million milligrams of LPs. We developed a method 
to hydrolyze the LPs, producing 36 million milligrams of monophosphoryl 
Lipid a (MPLa),  which unlike, LPs, when linking to the toll-Like receptor 4, 
does not trigger, from the production of cytocins, the inflammatory reaction, 
but stimulates, by means of production of interferons, the activation of the t 
linphocits.  
 the pertussis vaccine, in the wdtP, is tested before it is liberated for 
use, by the induction of protection against a strain of Bordetella, chosen for its 
virulence. It is injected directly into mice cerebrum, killing those which are not 
protected. We discovered that one of the subunits of the pertussis toxin, whose 
gene was introduced in the BCG vaccine, was capable of protecting the mice 
against the virulent Bordetella strain, without producing antibodies. Contrary to 
what was believed, it is not the antibodies induced by the vaccine, but the cellular 
immunity it induces that creates the immunological memory. 
 Butantan has been studying the role of cellular immunity induced by the 
flu vaccine. a new adjuvant was developed and tested in mice, which includes 
MPLa and aluminum hydroxide, seeking to increase in the flu vaccine the 
humoral and cellular response that allows a four-fold reduction in  the quantity 
of antigens in the vaccine formulation, permitting increased production at the 
seasonal flu vaccine plant from 20 million in four months to 80 million, obviously 
reducing the cost of the vaccine.
 the choice made in 2008 of the strains of the seasonal flu vaccine for 
the southern hemisphere created problems, because of the low productivity 
and low  immunogenicity. For the H5n1 vaccine for the pandemic, it is already 
known that the vaccines built by reverse genetic engineering, producing a dna 
using the viral Rna as a mold, and making some modifications to attenuate the 
virus, result in a vaccine that demands 80 micrograms per dose (the seasonal 
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vaccine uses only 15 micrograms for each one of the three strains). It is essential 
to use an adjuvant to reduce the quantity of the H5n1 antigen per dose of 
vaccine, which multiplies the installed capacity that would be mobilized in 
case of a pandemic. upon testing the adjuvant MPa (produced from the LPs 
of a salmonella) in mice, the need was found to add 100 micrograms. When 
emulsified with squalene, the quantity to be added was 100 times less. squalene is 
an oily compound isolated from sharks, which are now threatened with extinction 
and which will have to be substituted by a synthetic compound, which is much 
more expensive. a child vaccinated with wdtP receives,  with each dose, 400 
micrograms of LPs, corresponding to nearly 200 micrograms of MPLa, which 
usually does not cause serious collateral effects.  
 an important discovery was recently made. the collateral effects of the 
pertussis vaccine, which occur in one of every two thousand vaccinated children, 
are due to a genetic defect that affects a a sodium transporter of the synapses. 
at this time it is impossible to detect this mutation in the children who must be 
vaccinated. this does not decrease the value of the dtPlow, which has proved to 
be an effective and less toxic vaccine without an increase in costs. 
 one of the problems is protecting babies against whopping cough before 
the fourth month, when they receive the second dose of dtP. We were able to 
create a vaccine to be administered in maternity wards, substituting the BCG 
for a BCG that has included in its genome the s1 subunit of the pertussis toxin 
In India, a mother 
consoles her son believed to 
have Japanese encephalitis.
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which is associated to the hepatitis B vaccine, protecting the baby against the 
possible transmission of hepatitis B from contact with maternal blood. there 
are preliminary indications that the s1 subunit has adjuvant effect and should 
stimulate the protection given by the BCG against tuberculosis and, probably, as 
onco-BCG.
 Vaccine against rabies and leishmaniasis
 For decades,   Butantan produced a vaccine against rabies by inoculating the 
virus in the cerebrum of one-day old mice (before they begin to produce myelin). 
the vaccine was a portion of macerated cerebrum. It did not guarantee reliability 
and was particularly dangerous, because small quantities of cerebral mice myelin 
produced antibodies for the myelin of the person vaccinated, leading to Guillain-
Barré syndrome. as we did with the BCG plant, we simply stopped production of 
this vaccine and developed  veRo cells, achieving the highest reported yield per 
liter of the culture. We already meet demand in Brazil and are building a larger 
plant to meet demand for countries that do not have production capacity. 
 a derivative of this technology is the anti canine-rabies vaccine, produced 
in BHK cells (used to immunize horses to produce the anti-rabies serum) which 
must substitute the  Fuenzalida Palácios vaccine, which the Ministry of Health 
purchased. this vaccine and the vaccine for human use and the anti-rabies serum 
are essential for meeting demand in asia and africa.
 In collaboration with the university of Washington (the Infectious 
disease Research Institute, IdRI, in seattle), we are developing a combined 
rabies, leshmaniasis vaccine for dogs, which would block the transmission of two 
diseases to humans. these studies have the participation of the Federal university 
of Minas Gerais and of Fiocruz in Bahia.
 “Translational”  Studies  – public-private partnerships
 at times a word becomes associated to a trend and acquires a new 
connotation. “translational”  research involves the transfer of research from 
the laboratory to clinical trial and production. the use of this neologism 
became obvious to us when we assumed the renovation of production of 
immunobiologicals, which society and the government itself demand: products 
made available to society to resolve individual and public health problems.  
this process had to be reinvented in a country where research gives priority 
to publication, leaving it up to industry to “translate” the knowledge into 
application. If this pragmatic vision destroys basic research and the ability of the 
scientific community to map new knowledge and where it is taken, we will not 
escape from underdevelopment. We cannot platonically accompany research that 
advances at frightening speed, without our professors and researchers having 
the liberty to develop original scientific research. Brazil has achieved important 
progress that should accelerate rapidly. nevertheless,  we cannot be content 
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simply with scientific publications in high-level journals. they do not lead to 
“translation”. the teaching staff at universities do not develop technology, nor do 
they have the ability or the facilities to conceive an efficient, low cost and quality 
industrial production process capable of meeting societal demands. this role is 
being substituted by the patent and by the intention of the government to share 
income from patents with researchers.  Contrary to what takes place in the First 
World, where part of the public funding  generates at least “proof of principles” 
as a basis for their transformation in product, private companies in Brazil do 
not have the competence, appetite, financial or human resources to conduct this 
phase that is essential to development. In comparison with advanced countries, 
the funding for basic research and for the small staff of researchers are relatively 
greater (when considering salaries, infrastructure and frequently equipment and 
breeding facilities are paid by the institutional budget). In a simplistic vision, it 
is enough to offer resources and the private company will do the development, 
using the deposited patents. Private and even government companies are looking 
for black boxes and answers that  researchers don’t have such as technological 
processes from which they can obtain raw materials; suppliers of industrial 
equipment; how to build the black box; the demand for energy and water and 
where to find trained technicians. 
 this is the complex that we have to develop and implant in the 
BioIndustrial division of Butantan. the two dozen researchers at the 
Biotechnology Center attract dozens of graduate students, without whom the 
research would not advance. they are ready to give priority to projects with 
social impact, even while they have the liberty to explore others. the Production 
division plans the laboratory for production of vaccines, without intervention 
of the “specialized” firms that do not have real experience in the production of 
biological products. 
 We have been sought by Brazilian and foreign companies to open doors to 
public-private partnerships. this would transform Butantan into a development 
center that the company does not have, nor in which it is interested in investing, 
even if subsidized by the government. the state  pharmaceutical industry behaves 
like the private sector, in that it does not invest in development and innovation. 
For its part, if Butantan dedicated itself solely to development, without 
production, it would never improve or even truly test the supposedly developed 
process. even once production is installed,  Butantan’s legal and financial 
structure allows, given certain criteria, periodic introduction of technological 
modifications that improve the product or production, which does not take place 
in a private sector company, which maintains a plant and process while it obtains 
from it  products that have a market, creating profits  without new investments. 
Many innovations in the pharmaceutical industry, as has been denounced in 
dozens of books, are simply minor and cosmetic alterations in a medication 
that do not provide the new product greater advantages and benefits than the 
traditional one. 
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 Limited by the capacity of our small staff, we sought alternatives. We are 
not in the market for closed technologies and we are associating ourselves with 
large institutes such as the national Institute of Health (nIH), transforming 
the knowledge generated into technology and production. We began with the 
pentavalent rotavirus vaccine, opening the route for other producers in India 
and China, which along with us reached will reach nearly 50% of the world’s 
population of children in each location with the frequent serotypes. PatH, with 
resources from the Bill and Melinda Gates Foundation, is assisting the producers 
of this vaccine, which would cover the prevalent virus in each region and would 
reduce the cost of the vaccine by about half of the cost of the monovalent vaccine 
that was imported to Brazil. the agreement reached three years ago to produce 
rotavirus followed another for the quadrivalent dengue vaccine, and the Pediatric 
dengue vaccine Initiative, once again with resources from the Gates Foundation, 
is giving priority to assisting Butantan. In the two cases, the nIH has concrete 
evidence that the vaccines are safe and probably effective. the Butantan-nIH 
partnership allows completing the technological development, testing the vaccine 
and producing for Brazil and some other developing countries.  In this model 
in progress, the partnership is basically public (Butantan)-public (nIH). In 
other countries where there are no longer public institutes such as Butantan, the 
agreements are with private companies.  
Partnerships 
Product Partnerships Fundação Butantan  
And others
Pentavalent Rotavírus NIH + PATH
Tetravalent Dengue NIH + PDVI
Celullar Pneumococo Univ. Harvard + PATH
Parasitic vaccines Sabin Institute
Leishmaniasis-canine rabies IDRI – Univ. Washington
Vaccines and monoclonals for câncer Fundação Ludwig
other partnerships include one with Harvard university, with support 
from PatH, to develop a cellular vaccine against pneumococcos. this vaccine 
is the result of an internal project at Butantan, which should give origin to a 
vaccine that would cost some us$ 1-2 per dose, instead of the us$53 of the 
conjugated 7-valent vaccine. In conjunction with the sabin Institute-George 
Washington university, we are contributing to the development of a vaccine 
against worms  (necator and schistosoma). two months do not pass without 
another institution coming to Butantan to discuss a new project. the same has 
occurred with Brazilian pharmaceutical companies, with which we are negotiating 
partnerships. these contacts presuppose that Butantan comes to produce vaccines 
and other biological products, offering them at reduced cost to the Ministry of 
Health, which serves the government  market, and to private companies that 
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supply the open market. In this way, it is Butantan that assumes the risk of capital 
investment. this is the agreement for the botulinic toxin type a, which in the 
public sector is used for certain spastic diseases, and in the private sector mostly 
for aesthetic purposes. another type of public-private association began to arise 
where private companies sought Butantan to develop technology for the private 
company. In this model, Butantan conducts the development, which implies the 
construction or use of a pilot plant with Good Manufacturing Practices (GMP).  
the product can then be clinically tested and the technology transferred to the 
private company, which will pay royalties to Butantan. 
 despite some of the agreements reached, the companies react immediately 
to the potential market and profit. they know that it is impossible to 
compete with products imported in bulk, for either the private or even the 
government-owned companies. this is the case of Butantan’s projects to produce 
erythropoietin  and 
alpha interferon with a pharmaceutical company, a market that disappeared 
when Farmanguinhos began to import these products. other private companies 
import the bulk product manufactured in China at very low prices, which makes 
competition unviable with a better quality product manufactured in Brazil. 
 the research-development production facilities provides Butantan return 
on its investments and make it less dependent on funding, and also allows true 
technological development. the interruption of this link, in which the private 
industry and even the government see Butantan as a development center that fills 
the deficiency of private industry, which assumes long term investments and risks, 
would lead rapidly to the deterioration of what the Institute represents to the 
country and society. We cannot convert ourselves simply into a supplier of what 
the private company wants. to not be killed by predatory actions, which they 
assume are the responsibility of the government to business, we must find a form 
of symbiosis that contributes to the benefit of society. 
Surfactant: the pre-vaccinal-hemoderivatives solution
 the  potential exists to completely eliminate some viral diseases from 
the planet. until now, the only successfully concluded case is smallpox, which 
is now totally extinct. It appears that polio, which has been eliminated from the 
americas, may soon be extinct. nevertheless, countries with a deficient public 
health structure or even those that produce and export the vaccine, but do not 
use it in sufficient quantity, allow polio to survive and be transferred by travelers 
to other countries, which obliges those countries where polio has been eradicated 
to continue vaccinations. Rubella was nearly eliminated from the americas, but 
wound up reappearing after arriving with travelers. even with safe and effective 
vaccines, diseases caused by viruses or bacteria that survive in animals or even live 
freely can be controlled, but not become extinct. 
 With the introduction of universal vaccination campaigns in Brazil, 
child mortality has been reduced and in 2006 was 25/1,000 live births. In 
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são Paulo state it fell to 13/1,000, which is still much higher than countries 
such as sweden and Cuba. Half of the mortality represents neonatal mortality, 
prior to the application of the vaccine. vaccines that can be administered in the 
maternity ward, such as BCG (for tuberculosis) and those for hepatitis B, can 
reduce mortality in the first months of life. other diseases, such as whopping 
cough, are frequent and deadly before the fourth month of life, requiring 
vaccination with dtP in the second and fourth month.  Considerable reduction 
of whopping cough, deadly for newborns, should occur with the application of 
the recombinant BCG for the s1 subunit of the pertussis toxin.
 nearly 50% of neonatal mortality is caused by pulmonary immaturity, 
which impedes the opening of the alveolas with a child’s first cry. the immaturity 
is caused by a lack of surfactant, a complex lipoprotein, which can be substituted 
by one isolated from pig or cow lungs. In less than 15 minutes, babies with this 
condition can suffocate to death, so the surfactant needs to be available in the 
delivery room. the cost of the imported surfactant is some R$ 300-500 per 
dose. thus the supply of nearly 100 thousand doses of surfactant per year is 
economically unviable. Butantan developed the production of the surfactant by an 
original  process that allows its production for about R$ 100 per dose, thanks to 
the recycling of two of the raw materials, the solvent that extracts this surfactant 
from the surface of the alveolars, and the purification resin, reducing the cost. 
 this product, already clinically tested, is simply awaiting registration 
by Brazil`s national sanitary Inspection agency  (anvisa), and can save 300 
babies per day, who now die from suffocation while their mothers watch; and 
who become pregnant again at the cost of the national social security agency 
(Inss). 
 In addition to the phospholipids, the basic surfactant contains two 
indispensable hydrophobic proteins and a hydrophilic (a) protein, which has a 
similar structure to the protein of the C1q complement and is also a collectin, 
which links microorganisms, defending the organism from infection. Its 
production would be particularly useful for the production of a special surfactant, 
to which would be added tobramicine, which could be used in the treatment of 
pneumonia, even that produced by pseudomons common in hospital infections. 
 according to the Brazilian Constitution, plasma and its byproducts cannot 
be sold. since 1993, Butantan has attempted to develop a plant for fractioning 
human plasma, which was impeded (because it did not have access to the plasma) 
by what is known as the “vampire mafia”, which mediated importation of the 
hemoderivatives. as an alternative, the plasma was exported for processing. 
despite this problem, the idea was maintained to mount a processing center 
using the Cohn method in which proteins are precipitated with alcohol at 
low temperatures. this process, which was developed during World War II, 
continues to be used due to the international monopoly that does not seek to 
inovate and substitute its plants. Plasma contains about one hundred different 
proteins. the vIII and IX factors are isolated by cryoprepicitation because they 
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are poorly soluble at low temperatures, but their recovery does not reach 50%, 
which opened the market for recombinants, giving insufficient attention to the 
natural factors, which can now be isolated free of virus, without the expense for 
acquisition of more than 75% of the recombinant factors.  the plasma without the 
factors is precipitated with variable concentrations of alcohol, at different pH and 
temperature, to obtain albumin (for which there is now limited demand) and the 
immunoglobulins. In the Cohn method, the vIII and IX factors represent 37% 
of the value of the plasma and immunoglobulin products 46%.  Finally, Butantan 
began the construction of its plasma processing plant using only chromatography, 
making it the most modern plant existing. Without using cryoprecipitation or 
alcohol, it will be possible to recover a higher number of proteins with medical 
application. one of them is alpha-1 antitripsin, which inhibits the elastase 
liberated by the neutrophiles that accumulate during the pulmonary infection 
processes, and which were the cause of death during the flu pandemic of 1918, 
because they suffocated the victims. the alpha-1 antripsin can be associated to 
the surfactant in the treatment of pneumonia. 
 Genome and more vaccines
 the Biotechnology Center participated in mapping the genome of 
the Xillela, which opened new perspectives for the entrance of Butantan into 
molecular biology. Complete genomes of schistosoma and  of Leptospira were 
important contributions of the Center’s Molecular Biology group, which has 
the potential to indicate proteins that could be transformed into vaccines. 
We abandoned, as we mentioned above, the production of erythropoieti and 
interferon- g, due to the invasion of imported products. We will invest once again 
in the porcine vIII factor as a low cost solution for grave hemophiliacs who 
are resistant to the natural or recombinant vIII factor. We continue to invest, 
even without the desired intensity, in the vaccines for HPv whose cost would 
practically absorb all the resources of the Ministry of Health.
 We live in a country with great potential to become advanced if we 
concentrate on our priorities and maintain, in equilibrium with scientific research, 
a responsible pragmatic attitude. this is what guides the immunobiological 
program at Butantan.
 
estudos avançados 22 (64), 2008170
AbstrAct – Butantan creates new technologies and industrial processes for vaccines and 
other immunobiologicals, supplying 150 million doses of antigen vaccines per year, which 
constitute 82% of all vaccines in the country, at affordable prices which are provided free 
to all children and older adults. new developments include a pertussis vaccine that can be 
produced at the same price as the traditional vaccine by a process that also yields an adjuvant 
that  increases the efficacy of seasonal and avian influenza vaccines four-fold, reducing cost 
and increasing plant capacity; a technology which results in the highest industrial yield 
of human rabies vaccine to date, a combined vaccine for use in maternity wards for BCG-
hepatitis B and pertussis and a lung surfactant that will decrease prenatal mortality not 
solved with vaccines. In collaboration with nIH, Path and PdvI, Butantan is beginning 
production and assay of rotavirus and dengue vaccines.
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